Cargando…

Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States

AIM: To assess adherence and discontinuation of injectable glucagon-like peptide-1 receptor agonists (GLP-1 RA) at 12 and 24 months among adult type 2 diabetes mellitus (T2DM) patients in the United States initiating GLP-1 RA using the administrative claims-based database, Optum Clinformatics(®) Dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weiss, Tracey, Carr, Richard D, Pal, Sampriti, Yang, Lingfeng, Sawhney, Baanie, Boggs, Robert, Rajpathak, Swapnil, Iglay, Kristy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708309/ https://www.ncbi.nlm.nih.gov/pubmed/33273810 http://dx.doi.org/10.2147/PPA.S277676

Ejemplares similares

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
por: Weiss, Tracey, et al.
Publicado: (2022)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Dose distribution and up‐titration patterns of metformin monotherapy in patients with type 2 diabetes
por: Iglay, Kristy, et al.
Publicado: (2019)

Metformin adherence and discontinuation among patients with type 2 diabetes: A retrospective cohort study
por: Tang, Yuexin, et al.
Publicado: (2020)

Severity of hypoglycaemia and health‐related quality of life, work productivity and healthcare costs in patients with type 2 diabetes in Europe
por: Pawaskar, Manjiri, et al.
Publicado: (2018)

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
por: Chai, Shangyu, et al.
Publicado: (2022)

Effects of conformance to type 2 diabetes guidelines on health care resource utilization, clinical outcomes, and cost: A retrospective claims analysis
por: Mehta, Rajesh R., et al.
Publicado: (2020)

Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
por: Lautsch, Dominik, et al.
Publicado: (2019)

Effect of Medication Copayment on Adherence and Discontinuation in Medicare Beneficiaries with Type 2 Diabetes: A Retrospective Administrative Claims Database Analysis
por: Pawaskar, Manjiri D., et al.
Publicado: (2018)

Individualized HbA(1c) Goals, and Patient Awareness and Attainment of Goals in Type 2 Diabetes Mellitus: A Real-World Multinational Survey
por: Lautsch, Dominik, et al.
Publicado: (2021)

Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data
por: Weiss, Tracey J., et al.
Publicado: (2022)

Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event
por: Butler, Javed, et al.
Publicado: (2020)

Proximal Predictors of Long-Term Discontinuance with Noninsulin Antihyperglycemic Agents
por: Stuart, Bruce C., et al.
Publicado: (2016)

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
por: Norrbacka, Kirsi, et al.
Publicado: (2021)

Association Between Switching to a High-Deductible Health Plan and Discontinuation of Type 2 Diabetes Treatment
por: Fendrick, A. Mark, et al.
Publicado: (2019)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
por: Onoviran, Olusola F., et al.
Publicado: (2019)

Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis
por: Chai, Shangyu, et al.
Publicado: (2023)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
por: Tang, Hsin-Chieh, et al.
Publicado: (2014)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Cho, Young Min, et al.
Publicado: (2013)

The Burden of Cervical Conization in Privately Insured Young and Mid-Adult Women in the United States
por: Saxena, Kunal, et al.
Publicado: (2023)

Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes
por: Tunceli, Kaan, et al.
Publicado: (2015)

Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus
por: Pelle, Maria Chiara, et al.
Publicado: (2023)

Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
por: Yan, Yilong, et al.
Publicado: (2023)

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide
por: Alatorre, Carlos, et al.
Publicado: (2017)

Reasons for discontinuing insulin and factors associated with insulin discontinuation in patients with type 2 diabetes mellitus: a real-world evidence study
por: Wu, Jianmin, et al.
Publicado: (2021)

Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes Mellitus
por: Tang, Yuexin, et al.
Publicado: (2018)

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement
por: Giorgino, Francesco, et al.
Publicado: (2018)

The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
por: Brice, Kira R., et al.
Publicado: (2011)

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2020)

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Conformation Transition of Intracellular Part of Glucagon Receptor in Complex With Agonist Glucagon by Conventional and Accelerated Molecular Dynamics Simulations
por: Bai, Qifeng, et al.
Publicado: (2019)

Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2014)

Real‐world weight change among patients treated with glucagon‐like peptide‐1 receptor agonist, dipeptidyl peptidase‐4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence
por: Carls, G. S., et al.
Publicado: (2017)

Searching for the Secret of Stickiness: How Biofilms Adhere to Surfaces
por: Jiang, Zhaowei, et al.
Publicado: (2021)

Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States
por: Puenpatom, Amy, et al.
Publicado: (2017)

SUN-236 Testosterone and Glucagon-Like Peptide-1 Agonists for Type 2 Diabetes Mellitus: A Prospective Cohort Study
por: Graybill, Sky
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gu53880rfrdpks2j9nju6smasa